Taken together, increased levels of CAR and DSG2 could help target oncolytic adenovirus vectors for use as a therapeutic tool in lung cancer [5,21]; however, they also appear to indicate inferior survival outcomes in NSCLC [6,7,9,12,18,25,26,35]. Here, DSG2 is linked to lung cancer.